Peter Wingrove Peter Wingrove @SmartAsDaddy

Smart As Daddy

Stage IV prostate cancer. Dad. Husband. Son. Still here.
Sharing what nobody tells you.

NORMAL < 4
4,056 PSA at diagnosis February 2025 · normal is under 4
0.12 Twelve months later No active tumours

The dragon is sleeping

4,056
PSA at diagnosis
(normal < 4)
0.12
PSA March 2026
no active tumours
52
Age at diagnosis
GP said too young
7–10+
Years projected
up from 2–4
Read My Story Follow the Campaign

The Campaign

The case for screening. In numbers.

Prostate cancer is now the most commonly diagnosed cancer in the UK. There is no national screening programme. These numbers explain why that has to change.

1 in 2
UK prostate cancer diagnoses are made at stage 3 or 4 — when the cancer has already spread.
Prostate cancer is curable if found early. A national screening programme finds it early.
NHS Digital, Cancer Registration Statistics England 2022, Commons Library Dec 2024
#1

Most commonly diagnosed cancer in the UK — having overtaken breast cancer.

Prostate Cancer UK / NHS England
64,000+

New prostate cancer cases in the UK every year — around 175 every single day.

NHS England Cancer Registration Statistics 2022
600,000

Men living with prostate cancer in the UK today — up 100,000 since 2020.

Macmillan Cancer Support, 2026
~12,000

Men who die from prostate cancer in the UK every year — one every 45 minutes.

Prostate Cancer UK / NHS England
See all the numbers ▼
~100%

Five-year survival at stage 1. The same disease that kills ~12,000 men a year is almost entirely survivable — when found early enough.

Cancer Research UK
4.7×

Men with stage IV are nearly five times more likely to lose their jobs. Late diagnosis threatens your livelihood and your family’s financial security.

LAPCD study, UK
No invite

Unlike breast, bowel, or cervical cancer, men are not invited for routine prostate screening on the NHS.

NHS / UK NSC
1 in 4

Black men face a 1 in 4 lifetime risk — double the average. The NSC’s final 2026 decision excluded them from targeted screening.

Prostate Cancer UK
1 in 8

Men in the UK will be diagnosed at some point. Most will have no symptoms in the early stages.

Prostate Cancer UK
Withdrawn

In August 2026 the Government withdrew the PCRMP — the 2002 framework behind men’s informed choice on PSA testing. Men without symptoms can still ask their GP about the test.

DHSC, August 2026
£27

The approximate cost of a PSA blood test. The test that found my cancer. The test I had to argue for.

NHS reference cost
June 2026

The Health Secretary accepted the NSC recommendation against population screening. A £20m research investment was announced, including expanding the TRANSFORM trial. The wider population remains without a systematic screening invitation.

UK NSC / DHSC, June 2026
TRANSFORM

A major UK trial testing PSA + MRI as the basis for national screening. Results expected over the coming years.

TRANSFORM Trial / NHS England
7–10+ yrs

The time my doctors say I may have. I’m using every day of it to challenge the status quo — because if I’d been found at stage 1, I wouldn’t be racing against the clock.

Peter Wingrove, diagnosed 2025

The Campaign

No man should have to argue for this blood test.

“My GP didn’t think I needed a PSA test. I was 52 with a swollen abdomen, and he thought it was colorectal. I had to insist on the blood test. That insistence saved my life.”

Peter Wingrove — January 2025
Read more ▼

The UK screens routinely for breast cancer, bowel cancer, and cervical cancer. Women receive letters. Men receive nothing.

Prostate cancer is now the most commonly diagnosed cancer in the UK. A man dies from it every 45 minutes. And yet there is still no national screening programme — leaving men, GPs, and families to navigate a system that was simply not designed to catch this disease early.

In June 2026, the Health Secretary accepted the NSC’s recommendation against population screening. A £20 million research investment was announced, including the expansion of the TRANSFORM trial. A limited programme for BRCA2 carriers with family history was accepted. The wider population remains without a systematic invitation to be tested.

The Committee also considered men whose only known risk factor is a family history of the disease — and concluded that screening them was more likely to cause more harm than good. Men like me.

The TRANSFORM trial is testing whether combining PSA with MRI could provide a safe, accurate foundation for national screening. The evidence is being built. The ministerial decision has been made. It can be revisited when the evidence demands it.

More than 100,000 people signed the Parliamentary petition I championed calling for a national screening programme. The petition has closed. The campaign has not. The next phase is accountability — in Parliament, at the National Screening Committee, and in every GP surgery where a man asks about the test.

The TRANSFORM Trial: A major UK research programme testing PSA + MRI for more accurate, less harmful screening. Following the June 2026 ministerial decision, the Government committed £20 million to prostate cancer research — including expanding TRANSFORM. In the meantime, men concerned about prostate cancer can still discuss a PSA test with their GP — but most don’t know to ask.

100,000 voices.

More than 100,000 people signed the Parliamentary petition calling for a national prostate cancer screening programme — the threshold at which Parliament considers a petition for debate. It closed on 13 July 2026. The campaign continues.

Follow the Campaign

My Story Once upon a time.

In January 2025, I noticed something wasn’t right. My abdomen was swollen on one side. I’d been ignoring it for months — telling myself I was too young, too healthy. My wife Lynette finally insisted I see the GP.

Read more ▼

PSA: 4,056

My GP suspected colorectal cancer. But prostate cancer runs in my close family, and for years they had encouraged me to get my PSA checked. So I asked for the blood test. My GP didn’t think a 52-year-old with no prostate symptoms needed one. I had to insist. When the results came back, my PSA was 4,056. Normal is under 4. The colorectal consultant looked at the number and whistled. Then he said: “You don’t need me. You need a urologist. Urgently.”

The urologist examined my prostate. Then he said it out loud, just like that: “Oh yes. Definitely prostate cancer.” No MRI, no biopsy, no staging. He stepped out of the room, and came back with a clinical nurse specialist carrying a folder full of printed pamphlets — prostate cancer, hormone therapy. She took me into a side room to talk me through them. I hadn’t yet landed on “prostate cancer”. The folder already had.

I was only properly diagnosed after seeking a second opinion on Harley Street. That is where the MRI happened. The biopsy. The staging. Advanced metastatic prostate cancer — Gleason 4+4, later interpreted as 4+5 by another medical diagnostics team. It had spread from my prostate to the lymph nodes, upper and lower spine, chest, and several places in my hips. I was 52 years old. I had a three-year-old daughter. A wife. A father who had already lost one son.

Freefalling

What followed is something I can only describe as freefalling, with nothing beneath me and nowhere to grab onto. I remember walking through Regent’s Park in February, Lynette and my daughter in the playground around the corner. I was praying — begging for more time. Pleading not to leave them too soon.

Triplet therapy

I began triplet therapy on the NHS at Weston Park Cancer Centre, Sheffield: androgen deprivation therapy, androgen receptor pathway inhibitor, and seven rounds of chemotherapy. The treatment hit hard. After the first session I developed severe neutropenia — my white blood cells dropped to almost zero — and spent five days in hospital with a fever that wouldn’t break. Chemo 2 was on my birthday. I turned purple and went into anaphylaxis before the nurses brought me back with adrenaline. I rang the bell in September 2025, but knew that the war had not been won.

By March 2026, my PSA was 0.12. No active tumours. My original prognosis of 2–4 years has potentially become 7–10. I’m winning — not cured, but winning.

What the numbers don’t tell you

What the numbers cannot capture is what treatment actually feels like from the inside. Within the first week on ADT, I was hit by a fatigue unlike anything I had ever experienced — not tiredness, but a physical heaviness that made even ordinary tasks feel like enormous effort. Bone pain in my back and legs — often so bad I can’t concentrate and can barely even sit up straight, let alone walk. A brain fog that turned concentration into a daily battle. I have not been able to work since I started treatment. I cannot complete a full day of meaningful activity, intellectual or physical. This is not exceptional — it is the common reality for men on long-term hormone therapy for advanced prostate cancer. Caught at stage 1 or 2, many men are treated with surgery or radiotherapy alone and never experience this. Caught late, as I was, the treatment that keeps you alive takes significant parts of your life away — sometimes permanently.

The Sleeping Dragon

The dragon inside me is not dead. He is sleeping. We have to keep him sleeping.

The Sleeping Dragon — Peter Wingrove, 2025

I needed a way to hold the reality of palliative care without being destroyed by it. Not false hope. Not despair. Something in between — a liveable truth. I invented the Sleeping Dragon for myself first: the cancer is dormant, not gone. The treatment goal is to keep it sleeping for as long as possible.

And then I had to explain it to my daughter. Because she believes medicine makes people better. Because she was going to ask why Daddy still takes tablets if Daddy is better. So the Sleeping Dragon became her explanation too.

The Sleeping Dragon — a blue superhero watching over a sleeping dragon
The Sleeping Dragon. Created to explain stage IV palliative cancer — first to myself, then to my three-year-old daughter.

I’m not sharing this story for sympathy. I’m sharing it because prostate cancer is now the most commonly diagnosed cancer in the UK — and there is still no national screening programme. I had to argue with my GP for the blood test that saved my life. No man should have to do that.



Media & Speaking

A patient voice with a professional perspective.

Peter Wingrove spent a decade leading UK and international charities — raising millions, building high-performing teams, and navigating the intersection of healthcare, policy, and public advocacy. He brings that experience to everything he does as Smart As Daddy.

  • CEO, Shawmind National Mental Health Charity (2019–2024)
  • MBA, Cornell University Johnson School & UCT Graduate School of Business
  • Founded the GSB Foundation, raising £2.5 million in two years
  • Designed a £2 million annual MBA grant programme
  • Stage IV metastatic prostate cancer — Gleason 4+4, diagnosed 2025
  • PSA: 4,056 → 0.12 in 12 months, thanks to prayer and triplet therapy
  • Prostate Cancer Awareness Campaigner

Available to speak or write on:

Prostate Cancer Patient Perspective The Case for National Screening Men’s Mental Health Fatherhood & Serious Illness Navigating the NHS Palliative Care — Living With, Not Dying From What Nobody Tells You About Cancer Treatment Leadership Through Crisis

Get in Touch

If you’re a journalist, broadcaster, charity, event organiser, or policymaker and you’d like to talk — I’d love to hear from you. Whether it’s an interview, a panel, a keynote, or a collaboration, my inbox is open.

peter@smartasdaddy.com

Peter Wingrove is available for media interviews, podcast appearances, conference keynotes, charity events, and health sector panels. A full media kit is available on request.

Medical disclaimer: The content on this site reflects Peter Wingrove’s personal experience of prostate cancer diagnosis and treatment. It does not constitute medical advice. Always consult your GP or specialist healthcare team regarding your own health. Peter’s treatment pathway is palliative, not curative — his PSA numbers reflect successful disease management, not a cure.

© 2026 Smart As Daddy / Peter Wingrove. All rights reserved.